158 related articles for article (PubMed ID: 9785061)
1. Factors affecting high-density lipoproteins.
Gordon DJ
Endocrinol Metab Clin North Am; 1998 Sep; 27(3):699-709, xi. PubMed ID: 9785061
[TBL] [Abstract][Full Text] [Related]
2. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
Isles CG; Paterson JR
QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551
[TBL] [Abstract][Full Text] [Related]
3. Role of circulating high-density lipoprotein and triglycerides in coronary artery disease: risk and prevention.
Gordon DJ
Endocrinol Metab Clin North Am; 1990 Jun; 19(2):299-309. PubMed ID: 2192875
[TBL] [Abstract][Full Text] [Related]
4. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
Evans M; Roberts A; Davies S; Rees A
Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
[TBL] [Abstract][Full Text] [Related]
5. Serum high density lipoprotein cholesterol levels in Chinese healthy subjects and patients with certain diseases.
Cai HJ; Li ZX; Yang SM
Atherosclerosis; 1982 Jun; 43(2-3):197-207. PubMed ID: 7115460
[TBL] [Abstract][Full Text] [Related]
6. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
Chapman MJ; Assmann G; Fruchart JC; Shepherd J; Sirtori C;
Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528
[TBL] [Abstract][Full Text] [Related]
7. Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial.
Brousseau ME; O'Connor JJ; Ordovas JM; Collins D; Otvos JD; Massov T; McNamara JR; Rubins HB; Robins SJ; Schaefer EJ
Arterioscler Thromb Vasc Biol; 2002 Jul; 22(7):1148-54. PubMed ID: 12117730
[TBL] [Abstract][Full Text] [Related]
8. New developments in the prevention of atherosclerosis in patients with low high-density lipoprotein cholesterol.
Brousseau ME; Schaefer EJ
Curr Atheroscler Rep; 2001 Sep; 3(5):365-72. PubMed ID: 11487447
[TBL] [Abstract][Full Text] [Related]
9. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
10. Perspectives in the treatment of dyslipidemias in the prevention of coronary heart disease.
Borgia MC; Medici F
Angiology; 1998 May; 49(5):339-48. PubMed ID: 9591525
[TBL] [Abstract][Full Text] [Related]
11. Correlates of high HDL cholesterol among women with coronary heart disease.
Bittner V; Simon JA; Fong J; Blumenthal RS; Newby K; Stefanick ML
Am Heart J; 2000 Feb; 139(2 Pt 1):288-96. PubMed ID: 10650302
[TBL] [Abstract][Full Text] [Related]
12. Lipids and cardiovascular disease: do the findings and therapy apply equally to men and women?
LaRosa JC
Womens Health Issues; 1992; 2(2):102-11; discussion 111-3. PubMed ID: 1617306
[TBL] [Abstract][Full Text] [Related]
13. Gemfibrozil prevents major coronary events by increasing HDL-cholesterol and more.
Doggrell SA
Expert Opin Pharmacother; 2001 Jul; 2(7):1187-9. PubMed ID: 11583069
[TBL] [Abstract][Full Text] [Related]
14. Are high-density lipoprotein and triglyceride levels important in secondary prevention: impressions from the BIP and VA-HIT trials.
Rizos E; Mikhailidis DP
Int J Cardiol; 2002 Mar; 82(3):199-207; discussion 207-8. PubMed ID: 11911905
[TBL] [Abstract][Full Text] [Related]
15. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.
Robins SJ; Collins D; Wittes JT; Papademetriou V; Deedwania PC; Schaefer EJ; McNamara JR; Kashyap ML; Hershman JM; Wexler LF; Rubins HB;
JAMA; 2001 Mar; 285(12):1585-91. PubMed ID: 11268266
[TBL] [Abstract][Full Text] [Related]
16. The emerging role of HDL cholesterol. Is it time to focus more energy on raising high-density lipoprotein levels?
Safeer RS; Cornell MO
Postgrad Med; 2000 Dec; 108(7):87-90, 93-8. PubMed ID: 11126145
[TBL] [Abstract][Full Text] [Related]
17. Effects of nonstatin lipid drug therapy on high-density lipoprotein metabolism.
Rader DJ
Am J Cardiol; 2003 Apr; 91(7A):18E-23E. PubMed ID: 12679199
[TBL] [Abstract][Full Text] [Related]
18. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
[TBL] [Abstract][Full Text] [Related]
19. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease.
Gotto AM
Am Heart J; 2002 Dec; 144(6 Suppl):S33-42. PubMed ID: 12486414
[TBL] [Abstract][Full Text] [Related]
20. Management of hypercholesterolaemia in postmenopausal women.
Davidson MH; Maki KC; Karp SK; Ingram KA
Drugs Aging; 2002; 19(3):169-78. PubMed ID: 12027776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
